- 2 Years of Immunotherapy for Advanced Lung Cancer Might Be Enough: Study
- AHA News: This Fitness Instructor Had a Stroke at 36
- Smoke From Wildfires Is Especially Tough If You Have Asthma. Here’s How to Protect Yourself
- Diabetes Med Metformin Might Help Prevent Long COVID
- FDA Panel Backs RSV Vaccine for Infants, Some Toddlers
- Young Adults’ Use of Hallucinogens Like Mushrooms, PCP Doubled in a Few Years: Study
- Disability a Growing Concern for U.S. Cancer Survivors
- Long Space Flights Could Take Toll on Astronauts’ Brains
- Seizures While Driving Highlight Importance of Early Diagnosis of Epilepsy
- Nutrient Taurine Might Help Extend Life, Animal Studies Show
Vonvendi Approved to Control Bleeding Disorder

Vonvendi has been approved to treat adults with von Willebrand disease (VWD), the most common inherited bleeding disorder.
VWD, affecting about 1 percent of the U.S. population, is caused by lack of a protein that’s essential for blood clotting. People with the disorder can develop severe bleeding from the nose, gums, intestines, muscles and joints. Women with VWD also can bleed excessively after a menstrual period or after giving birth.
Vonvendi, a genetically engineered (recombinant) form of the missing protein, was evaluated in clinical studies of 69 adults with VWD. Itching was the most common side effect, the FDA said Tuesday in a news release.
Vonvendi is produced by Baxalta, based in Westlake Village, Calif.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.